ADIAL PHARMACEUTICALS, INC. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
Form 8-K filed 2026-08-13 reports Item 5.02 (officer/director changes and compensation) and Item 8.01 (other events), but the filing metadata provided contains no substantive details regarding specific officers, departure dates, compensation amounts, or arrangement terms. The actual 8-K document content is not included in the submission metadata.
Why this rating
Officer changes are always material disclosures for micro-cap firms; however, specifics are absent. Cannot assess impact without names, roles, amounts.
Extracted items
- 5.02 exec change
- 8.01 other event
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.